Form 4: Centessa GC Sells Shares After Option Exercise
Insider Transaction Report
Centessa Pharmaceuticals General Counsel Iqbal J Hussain exercised stock options and subsequently sold 6,000 ordinary shares for a profit under a pre-arranged trading plan.
Summary
- Iqbal J Hussain, General Counsel of Centessa Pharmaceuticals plc, reported transactions on September 15, 2025.
- Exercised options to acquire 6,000 Ordinary Shares at an exercise price of $5.84 per share.
- Sold 6,000 Ordinary Shares at a weighted average price of $21.8501 per share, with prices ranging from $21.74 to $21.96.
- The sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2024.
- Following these transactions, direct beneficial ownership stands at 105,386 Ordinary Shares, with an additional 5,500 shares indirectly owned by a spouse.
- Remaining derivative securities include 233,559 Share Options.
Sentiment
Score: 5
Explanation: The transaction represents a profitable, pre-planned insider sale, which is generally neutral for company sentiment. While a sale by an insider can sometimes be viewed negatively, the 10b5-1 plan mitigates concerns of it being based on new, negative information.
Positives
- The General Counsel realized a significant profit by exercising options at $5.84 and selling shares at an average of $21.8501.
- The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new, undisclosed negative information.
Negatives
- An insider sale, even if planned, can sometimes be perceived as a lack of conviction in the company's near-term stock price appreciation.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: The sale by a General Counsel could be viewed neutrally to slightly negatively, though the 10b5-1 plan suggests it's a planned liquidity event rather than a reaction to new information. The significant profit realized by the insider highlights the value creation for executives through stock options.
Key Dates
| Date | Description |
|---|---|
| 02/19/2022 | Initial vesting date for 25% of the share option. |
| 09/14/2024 | Date Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 09/15/2025 | Date of option exercise and subsequent sale of ordinary shares. |
| 02/19/2031 | Expiration date of the share option. |
Keywords
Centessa Pharmaceuticals, CNTA, Iqbal J Hussain, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, General Counsel
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.